Company Description
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States.
The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development.
It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies.
Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
| Country | United States |
| Founded | 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Robert Lisicki |
Contact Details
Address: 1489 W. Warm Springs Road, Suite 110 Henderson, Nevada 89014 United States | |
| Phone | 702 825 9872 |
| Website | zurabio.com |
Stock Details
| Ticker Symbol | ZURA |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855644 |
| ISIN Number | KYG9TY5A1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert Lisicki | Chief Executive Officer and Director |
| Dr. Someit Sidhu M.D. | Founder and Director |
| Kimberly Ann Davis J.D. | Chief Operating Officer, Chief Legal Officer and Corporate Secretary |
| Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer and Head of Development |
| Eric Hyllengren | Chief Financial Officer |
| Dr. Gary Whale Ph.D. | Chief Technology Officer |
| Theresa Lowry | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2025 | SCHEDULE 13G | Filing |
| Jul 1, 2025 | 8-K | Current Report |
| Jun 4, 2025 | 8-K | Current Report |
| May 28, 2025 | SCHEDULE 13D | Filing |
| May 27, 2025 | 8-K | Current Report |
| May 23, 2025 | 8-K | Current Report |
| May 20, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | SCHEDULE 13G | Filing |
| May 8, 2025 | 10-Q | Quarterly Report |